Literature DB >> 29980980

Cerebrospinal Fluid C-Reactive Protein in Parkinson's Disease: Associations with Motor and Non-motor Symptoms.

Hossein Sanjari Moghaddam1, Zahra Valitabar1, Amir Ashraf-Ganjouei1, Mahtab Mojtahed Zadeh1, Farzaneh Ghazi Sherbaf1, Mohammad Hadi Aarabi2.   

Abstract

Parkinson' disease (PD) is characterized by motor symptoms including bradykinesia, resting tremor, postural instability, and rigidity and non-motor symptoms such as cognitive impairment, sleep disorder, and depression. Neuroinflammation has been recently implicated in pathophysiology of both motor and non-motor symptoms of PD. One of the most notable inflammatory proteins is C-reactive protein (CRP), which is elevated in the conditions of systemic inflammation. Using BioFIND database, we scrutinized the possible association between cerebrospinal fluid (CSF) levels of CRP and severity of PD motor and non-motor symptoms. Eighty-four healthy controls (HCs) and 109 PD subjects were entered into this study. A significant correlation was observed between CSF CRP levels and Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS part III) score and Montreal Cognitive Assessment (MoCA) score in PD patients. We found significant correlations between MoCA score and CSF CRP levels in female patients and between CSF CRP and MDS-UPDRS part III score and MoCA score in male patients. In linear regression, CSF CRP could predict 6.9 and 10% of changes in MDS-UPDRS part III score in all PD patients male PD patients, respectively. In summary, we confirmed that CSF concentrations of CRP are in correlation with motor and non-motor severity in PD subjects. Our findings suggest that neuroinflammation plays an important role in the initiation and probably progression of PD motor and non-motor symptoms, which may give us a better insight into the underlying pathologic mechanisms in PD.

Entities:  

Keywords:  C-reactive protein; Motor symptoms; Neuroinflammation; Non-motor symptoms; Parkinson’ disease

Mesh:

Substances:

Year:  2018        PMID: 29980980     DOI: 10.1007/s12017-018-8499-5

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  48 in total

1.  Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression.

Authors:  María Clara Pott Godoy; Carina Cintia Ferrari; Fernando Juan Pitossi
Journal:  J Neuroimmunol       Date:  2010-03-29       Impact factor: 3.478

2.  The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.

Authors:  Erdinç Dursun; Duygu Gezen-Ak; Haşmet Hanağası; Başar Bilgiç; Ebba Lohmann; Sibel Ertan; İrem L Atasoy; Merve Alaylıoğlu; Ömür Selin Araz; Burak Önal; Ayşegül Gündüz; Hülya Apaydın; Güneş Kızıltan; Turgut Ulutin; Hakan Gürvit; Selma Yılmazer
Journal:  J Neuroimmunol       Date:  2015-04-25       Impact factor: 3.478

3.  The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease.

Authors:  Matthew Menza; Roseanne Defronzo Dobkin; Humberto Marin; Margery H Mark; Michael Gara; Karina Bienfait; Allison Dicke; Alex Kusnekov
Journal:  Psychosomatics       Date:  2010 Nov-Dec       Impact factor: 2.386

4.  White Matter Changes Correlates of Peripheral Neuroinflammation in Patients with Parkinson's Disease.

Authors:  Maryam Haghshomar; Farzaneh Rahmani; Mohammad Hadi Aarabi; Shima Shahjouei; Soheila Sobhani; Maryam Rahmani
Journal:  Neuroscience       Date:  2017-11-08       Impact factor: 3.590

5.  Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease?

Authors:  Sharon Hassin-Baer; Oren S Cohen; Eli Vakil; Noa Molshazki; Ben-Ami Sela; Zeev Nitsan; Joab Chapman; David Tanne
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

Review 6.  Neuroimmune regulation in immunocompetence, acute illness, and healing.

Authors:  Istvan Berczi; Andres Quintanar-Stephano; Kalman Kovacs
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

Review 7.  Inflammation and neurodegeneration in Parkinson's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  Parkinsonism Relat Disord       Date:  2004-05       Impact factor: 4.891

8.  Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment.

Authors:  Daniel Lindqvist; Sara Hall; Yulia Surova; Henrietta M Nielsen; Shorena Janelidze; Lena Brundin; Oskar Hansson
Journal:  Brain Behav Immun       Date:  2013-07-31       Impact factor: 7.217

9.  The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism.

Authors:  Limin Zhang; Junqiang Yan; Yunqi Xu; Ling Long; Cansheng Zhu; Xiaohong Chen; Ying Jiang; Lijuan Yang; Lianfang Bian; Qing Wang
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

10.  Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.

Authors:  María Clara Pott Godoy; Rodolfo Tarelli; Carina Cintia Ferrari; Maria Inés Sarchi; Fernando Juan Pitossi
Journal:  Brain       Date:  2008-05-26       Impact factor: 13.501

View more
  6 in total

Review 1.  Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.

Authors:  Milan Zimmermann; Kathrin Brockmann
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

2.  High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients.

Authors:  Diego Santos-García; T de Deus Fonticoba; E Suárez Castro; A Aneiros Díaz; J M Paz González; M J Feal Panceiras; C García Sancho; S Jesús; P Mir; M Aguilar; P Pastor; J Hernández Vara; O de Fábregues-Boixar; V Puente; A Crespo Cuevas; I González-Aramburu; J Infante; F Carrillo Padilla; M Pueyo; S Escalante; N Bernardo; B Solano; A Cots Foraster; P Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2019-10-31       Impact factor: 3.575

3.  C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Xiaohui Qiu; Yousheng Xiao; Jingjing Wu; Lu Gan; Yanning Huang; Jin Wang
Journal:  Front Neurol       Date:  2019-04-17       Impact factor: 4.003

Review 4.  Parkinson disease and the immune system - associations, mechanisms and therapeutics.

Authors:  Eng-King Tan; Yin-Xia Chao; Andrew West; Ling-Ling Chan; Werner Poewe; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2020-04-24       Impact factor: 42.937

5.  Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure.

Authors:  Farzaneh Ghazi Sherbaf; Bahram Mohajer; Amir Ashraf-Ganjouei; Mahtab Mojtahed Zadeh; Ali Javinani; Hossein Sanjari Moghaddam; Mehdi Shirin Shandiz; Mohammad Hadi Aarabi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-02       Impact factor: 5.555

6.  Parkinson's Disease With Depression: The Correlations Between Neuroinflammatory Factors and Neurotransmitters in Cerebrospinal Fluid.

Authors:  Teng-Hong Lian; Peng Guo; Ya-Nan Zhang; Jing-Hui Li; Li-Xia Li; Du-Yu Ding; Da-Ning Li; Wei-Jiao Zhang; Hui-Ying Guan; Xiao-Min Wang; Wei Zhang
Journal:  Front Aging Neurosci       Date:  2020-10-23       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.